Teva Pharmaceutical has recieved USFDA approval of the generic equivalent to Evista (Raloxifene) Tablets, 60 mg, in the United States. Teva was first to file, making the product eligible for 180 days of marketing exclusivity.
Evista 60 mg Tablets marketed by Eli Lilly and Company, had annual sales of approximately USD824 million in the United States, according to IMS data as of December 2013.
Thomas Cueni on pricing and developing markets
In this exclusive interview, Thomas Cueni, director general of the International Federation of Pharmaceutical…